
    
      Eligible patients must be stable HF patients, NYHA class III who were hospitalised/treated
      for an episode of worsening HF within the last 12 months. This non-randomised FIH trial will
      enrol a total of 10 patients and the primary safety and technical endpoints will be assessed
      at 3 months. Safety measures will include an assessment of all adverse events. Subjects will
      remain on this study for 24 months.
    
  